FDC Limited
NSE: FDC · Pharmaceuticals
Snapshot
Unlock FDC Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
FDC Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of specialized formulations and active pharmaceutical ingredients. Its diverse product portfolio spans therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, and nutraceuticals.
Business Model
The company generates revenue through the sale of branded pharmaceutical formulations and active pharmaceutical ingredients in both domestic and international markets. It leverages a strong portfolio of established brands such as Zifi, Electral, and Enerzal to maintain market presence.
- Founded:1936
Growth Outlook
Growth is driven by the expansion of its specialized therapeutic segments and the continued demand for its established nutraceutical and oral rehydration brands. The company focuses on maintaining its competitive edge through its diverse product range and established brand equity.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and regulatory inspections by health authorities in India and international markets.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins for key pharmaceutical products.
- Market Competition. Intense competition from both domestic generic manufacturers and multinational corporations may exert pressure on market share and pricing power.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients and raw materials can disrupt production and affect operational profitability.
Price
Start your research today
Unlock AI insights, financials, peers and live data on FDC Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,171 Cr
TTM · consolidated
NET PROFIT
₹281 Cr
TTM · consolidated
EPS
₹17.29
TTM · consolidated
RETURN ON EQUITY
12.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.8%
TTM · consolidated
P/E
24.4x
Q4 FY26 · consolidated
EV/EBITDA
14.8x
Q4 FY26 · consolidated
EBITDA MARGIN
21.2%
TTM · consolidated
NET PROFIT MARGIN
17.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
FDC LimitedFDC | 5,431 | 24.39 | 14.83 | 3.0% | 21.2% | 12.1% | 15.8% | -15.0% |
Shilpa Medicare LimitedSHILPAMED | 6,974 | 42.78 | 29.45 | 19.6% | 28.9% | 10.0% | 13.2% | -31.6% |
Blue Jet Healthcare Ltd.BLUEJET | 6,062 | 41.13 | 27.96 | -8.0% | 38.3% | 20.8% | 27.7% | -38.6% |
Aarti Pharmalabs LimitedAARTIPHARM | 5,745 | 34.88 | 18.20 | -14.0% | 21.7% | 9.2% | 12.4% | -25.7% |
Supriya Lifescience LimitedSUPRIYA | 4,613 | 32.74 | 22.28 | 18.9% | 36.9% | 20.0% | 25.6% | +18.0% |
Innova Captab LimitedINNOVACAP | 3,954 | 41.08 | 24.48 | 31.1% | 15.4% | 14.2% | 16.3% | +11.7% |
As of Q4 FY26
Financials
FDC Limited
NSE: FDC · Pharmaceuticals
Snapshot
Unlock FDC Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
FDC Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of specialized formulations and active pharmaceutical ingredients. Its diverse product portfolio spans therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, and nutraceuticals.
Business Model
The company generates revenue through the sale of branded pharmaceutical formulations and active pharmaceutical ingredients in both domestic and international markets. It leverages a strong portfolio of established brands such as Zifi, Electral, and Enerzal to maintain market presence.
- Founded:1936
Growth Outlook
Growth is driven by the expansion of its specialized therapeutic segments and the continued demand for its established nutraceutical and oral rehydration brands. The company focuses on maintaining its competitive edge through its diverse product range and established brand equity.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and regulatory inspections by health authorities in India and international markets.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins for key pharmaceutical products.
- Market Competition. Intense competition from both domestic generic manufacturers and multinational corporations may exert pressure on market share and pricing power.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients and raw materials can disrupt production and affect operational profitability.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on FDC Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,171 Cr
TTM · consolidated
NET PROFIT
₹281 Cr
TTM · consolidated
EPS
₹17.29
TTM · consolidated
RETURN ON EQUITY
12.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.8%
TTM · consolidated
P/E
24.4x
Q4 FY26 · consolidated
EV/EBITDA
14.8x
Q4 FY26 · consolidated
EBITDA MARGIN
21.2%
TTM · consolidated
NET PROFIT MARGIN
17.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26